3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2016 by Memorial Sloan Kettering Cancer Center
Sponsor:
Collaborators:
Janssen Scientific Affairs, LLC
OHSU Knight Cancer Institute
Rutgers Cancer Institute of New Jersey
NorthShore University HealthSystem
Duke University
Feinberg School of Medicine, Northwestern University
Sidney Kimmel Comprehensive Cancer Center
University of North Carolina
Wayne State University
Perlmutter New York University Cancer Center
Weill Medical College of Cornell University
Ferring Pharmaceuticals
GU Research Network, LLC
University of California, Los Angeles
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT01751451
First received: December 14, 2012
Last updated: April 6, 2016
Last verified: April 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: October 2017
  Estimated Primary Completion Date: October 2017 (Final data collection date for primary outcome measure)